Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

US patent for CardioGenics signal amplification technology

The United States Patent & Trademark Office (USPTO) has issued CardioGenics patent no 7,964,415 covering its proprietary signal amplification technology, which is a key component of the technology that permits the ultra-sensitive performance of QL Care Analyzer.

QL Care Analyzer, a proprietary and ultra-sensitive point-of-care immuno-analyzer, will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests.

CardioGenics’ methodology for signal amplification enables a decrease in the amount of binding reagents used in immunoassay diagnostic tests, such as those to be performed on the QL Care Analyzer.

As part of its core proprietary technology, CardioGenics has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light.

CardioGenics’ proprietary microspheres technology and SAVAsphere magnetic beads are developed and marketed through the company’s Luxspheres subsidiary.